Interim report 1 January – 31 March 2024

Positive profitability trend driven by Medtech

		During the quarter, profitability strengthened in line with our priorities and organic sales increased by 4%. Labtech's sales performance was temporarily weaker, but the companies were largely able to defend their margins. Medtech delivered strong growth and it is gratifying to see a gradual improvement in profitability, driven in part by implemented improvement actions.
		Fredrik Dalborg, President and CEO

1 JANUARY – 31 MARCH 2024 (3 MONTHS)

• Net sales increased by 5% to SEK 2,570 m (2,457). The organic growth, excluding exchange rate changes, was 4%. 
• EBITA decreased by 20% to SEK 291 m (366), corresponding to an EBITA-margin of 11.3% (14.9). EBITA previous year included reversed contingent considerations of SEK 83 m. Adjusted for this EBITA increased by 3% and the EBITA margin previous year amounted to 11.5%.
• Profit for the period amounted to SEK 63 m (174).
• Earnings per share amounted to SEK 0.52 (1.43). Earnings per share for the last 12 months amounted to SEK 0.65 (3.54)
• Cash flow from operating activities amounted to SEK 97 m (105).

• The equity ratio was 39% (39).
• Return on working capital (P/WC) amounted to 46% (50).